Antibody-drug conjugates (ADCs) are a class of novel biopharmaceuticals composed of monoclonal antibodies linked to highly potent cytotoxic small molecule drugs through a bioactive linker. Their mechanism of action involves the monoclonal antibody specifically targeting cancer cells, followed by the small molecule drugs killing the cancer cells. Therefore, ADCs combine the high specificity and targeting characteristics of monoclonal antibody drugs with the efficiency of small molecule drugs in eliminating cancer cells, allowing the advantages of both antibody drugs and chemical drugs to work synergistically while reducing harm to biological systems.
The commonly used preparation of antibody-drug conjugates involves a two-step conjugation reaction. First, the antibody is combined with a linker to form an intermediate (antibody-linker), and then this intermediate is linked to a small molecule drug to generate the antibody-drug conjugate, as shown in the figure below.
Two-step reaction of antibody-drug conjugates (ADCs)
The following issues may arise during the reaction process:
1. Some antibodies and small molecule drugs cannot successfully conjugate; 2. Multiple binding sites (such as Cys, Lys residues) in antibodies may lead to heterogeneity due to different binding sites and quantities; 3. The higher hydrophobicity of small molecule drugs and varying numbers of conjugations to monoclonal antibodies may change the hydrophobicity of ADC drugs.
These unconjugated naked antibodies and cytotoxic small molecules, along with the heterogeneity of conjugated drugs, may affect the efficacy and safety of ADC drugs. Compared to monoclonal antibodies, the manufacturing process of ADCs is more complex. Therefore, to ensure the safety and efficacy of ADC drugs, quality monitoring is necessary. The drug-to-antibody ratio (DAR) is an important parameter to evaluate the manufacturing process and product quality of ADCs. Therefore, a comprehensive assessment of ADC drug structure, DAR, efficacy, and safety is essential before ADC filing. BTPK offers a variety of advanced chromatography and mass spectrometry instruments, combined with a professional bioinformatics analysis team, to provide you with rapid and accurate professional systematic antibody-drug conjugate analysis and evaluation services.
Detection Platform
• MALDI-TOF Mass Spectrometry
• ESI-TOF Mass Spectrometry
• UV/VIS Spectroscopy
• UV-MALDI Mass Spectrometry
• Reverse-phase High Performance Liquid Chromatography (RP-HPLC)
• Hydrophilic Interaction Chromatography (HILIC)
• Ion Exchange Chromatography (IEX)
• Hydrophobic Interaction Chromatography (HIC)
• Size Exclusion Chromatography (SEC)
ADCs Detection and Analysis Projects
BTPK provides a one-stop systematic analysis service for antibody-drug conjugates, divided into three modules: structural characterization, drug effect, and drug impurities, ensuring comprehensive systematic analysis and evaluation of the structure and efficacy of antibody-drug conjugates.
DAR Analysis of Antibody-drug Conjugates (ADCs)
Chinese/English Project Report
In the technical report, BTPK Biotech will provide you with a detailed bilingual technical report in Chinese/English, including:
1. Experimental Procedures (Chinese and English)
2. Related Mass Spectrometry Parameters (Chinese and English)
3. Raw Data
4. ADC Drug Analysis Results
One-stop Service for Antibody-drug Conjugates (ADCs) Analysis
You only need to place an order and send samples; BTPK one-stop service completes: sample processing, on-machine analysis, data analysis, project report
